Education
About Us
Working with TipRanks
Follow Us
Aptevo Therapeutics Inc (APVO)
NASDAQ:APVO
Total Valuation
Aptevo Therapeutics has a market cap or net worth of $18.03M. The enterprise value is -$2.95M.
Market Cap$18.03M
Enterprise Value-$2.95M
Share Statistics
Aptevo Therapeutics has 16,850,494 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding16,850,494
Owned by Insiders0.08%
Owned by Institutions1.01%
Financial Efficiency
Aptevo Therapeutics’s return on equity (ROE) is -5.07 and return on invested capital (ROIC) is -262.17%.
Return on Equity (ROE)-5.07
Return on Assets (ROA)-1.55
Return on Invested Capital (ROIC)-262.17%
Return on Capital Employed (ROCE)-2.62
Revenue Per Employee0.00
Profits Per Employee-652.16K
Employee Count37
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Aptevo Therapeutics is ―. Aptevo Therapeutics’s PEG ratio is 0.00051.
PE Ratio―
PS Ratio0.00
PB Ratio0.25
Price to Fair Value0.25
Price to FCF-0.05
Price to Operating Cash Flow-0.04
PEG Ratio0.00051
Income Statement
In the last 12 months, Aptevo Therapeutics had revenue of 0.00 and earned -24.13M in profits. Earnings per share was -1.75K.
Revenue0.00
Gross Profit-352.00K
Operating Income-24.60M
Pretax Income-24.13M
Net Income-24.13M
EBITDA-23.78M
Earnings Per Share (EPS)-1.75K
Cash Flow
In the last 12 months, operating cash flow was -26.11M and capital expenditures 0.00, giving a free cash flow of -26.11M billion.
Operating Cash Flow-26.11M
Free Cash Flow-26.11M
Free Cash Flow per Share-1.55
Dividends & Yields
Aptevo Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.03
52-Week Price Change-98.83%
50-Day Moving Average1.36
200-Day Moving Average7.71
Relative Strength Index (RSI)40.44
Average Volume (3m)11.64M
Important Dates
Aptevo Therapeutics upcoming earnings date is Apr 1, 2026, TBA (Confirmed).
Last Earnings DateNov 6, 2025
Next Earnings DateApr 1, 2026
Ex-Dividend Date―
Financial Position
Aptevo Therapeutics as a current ratio of 1.72, with Debt / Equity ratio of 64.52%
Current Ratio1.72
Quick Ratio1.72
Debt to Market Cap0.00
Net Debt to EBITDA0.17
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Aptevo Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Aptevo Therapeutics EV to EBITDA ratio is 0.08, with an EV/FCF ratio of 0.08.
EV to Sales0.00
EV to EBITDA0.08
EV to Free Cash Flow0.08
EV to Operating Cash Flow0.08
Balance Sheet
Aptevo Therapeutics has $21.06M in cash and marketable securities with $3.99M in debt, giving a net cash position of $17.07M billion.
Cash & Marketable Securities$21.06M
Total Debt$3.99M
Net Cash$17.07M
Net Cash Per Share$1.01
Tangible Book Value Per Share$344.42
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Aptevo Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target―
Price Target Upside―
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast99.02%